United States Patent 7,566,729 (Pirfenidone IPF With Liver-Biomarker–Guided Dose Reduction/Re-escalation): Scope, Claim Architecture, and Landscape
US Patent 7,566,729 claims a dose-management method for pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) who show liver-function biomarker abnormalities (grade 2) after pirfenidone administration. The core protected concept is a sequenced regimen: lower-dose treatment first, then restart at standard high doses (2400 mg/day or 2403 mg/day).
What is claimed? (Independent Claim Scope)
Claim 1: Core method structure
Claim 1 is the only independent claim provided and it defines a two-phase dosing sequence tied to a liver-biomarker trigger:
- Patient condition / trigger
- Patient has IPF
- Patient has grade 2 abnormality in one or more liver function biomarkers after pirfenidone administration
- Two-step dosing sequence
- (a) administering pirfenidone at doses lower than 2400 mg/day for a time period
- (b) administering pirfenidone at 2400 mg/day or 2403 mg/day
- Time period in (a) is not numeric in Claim 1
- Dependent claims define specific duration options and stoppage logic
Practical read for scope:
- The invention is not “pirfenidone for IPF” or “monitor liver enzymes.”
- It is a conditional dosing protocol that starts below the full dose threshold after grade 2 liver biomarker abnormality, then returns to full dosing at 2400 or 2403 mg/day.
Key scope boundaries embedded in Claim 1
- Lower-dose must be strictly below 2400 mg/day (with the specification in dependent claims using specific lower anchors such as 800, 1600, and variants).
- Re-escalation is capped at specific target doses:
- 2400 mg/day or 2403 mg/day.
- Trigger is specific to “grade 2” biomarker abnormality after pirfenidone
- The claims tie the dosing change to a prior exposure event, not prophylaxis.
How do dependent claims narrow the regimen? (Claim-by-Claim Coverage)
Claim 2: Hold then resume
Claim 2 narrows (a) by adding a discontinuation option:
- Prior to step (a), pirfenidone is discontinued until biomarkers are within normal limits.
Scope implication:
- Even if the claim base requires “doses lower than 2400 mg/day,” Claim 2 adds a wash/hold stage before dose reduction.
Claim 3: One-step low-dose
Claim 3 specifies (a) as:
- about 1600 mg/day or 1602 mg/day for about one week, or until biomarkers are within normal limits.
Scope implication:
- It covers a 1600/1602 mg/day down-titration path with a typical one-week duration, with biomarker-controlled termination.
Claim 4: Two-stage step-up
Claim 4 specifies (a) as a staged escalation:
- about 800 mg/day or 801 mg/day for about one week, or until normal limits
- then about 1600 mg/day or 1602 mg/day for about one week
Scope implication:
- It protects the 800 → 1600 staged recovery sequence prior to reaching full dose.
Claim 5: Discontinue one week (then 800 then 1600)
Claim 5 specifies an explicit interruption and reintroduction path:
- discontinuing pirfenidone for about one week, or until biomarkers are within normal limits
- then about 800 mg/day or 801 mg/day for about one week
- then about 1600 mg/day or 1602 mg/day for about one week
Scope implication:
- It locks in a three-event timeline: hold → 800 → 1600.
Claim 6: Dosing frequency/formulation context
Claim 6 specifies:
- pirfenidone is administered three times per day with food.
Scope implication:
- It narrows to the classic TID administration pattern with meals. A dosing schedule that avoids “three times per day with food” may not read on Claim 6 if Claim 1 is not satisfied or if Claim 6 is treated as narrowing.
Claim 7: Biomarker set
Claim 7 defines biomarkers as selected from:
- alanine transaminase (ALT)
- aspartate transaminase (AST)
- bilirubin
- alkaline phosphatase
Scope implication:
- A competitor method using only a different biomarker set may avoid the specific “selected from the group” limitation in Claim 7.
Claim 8: Measuring during low-dose phase
Claim 8 adds:
- measuring one or more biomarkers during step (a).
Scope implication:
- Protocols that change dosing without measuring during the low-dose phase may avoid Claim 8 (but could still fall under Claim 1-5 depending on how strictly the claim chain is enforced).
Claim 9: Specific biomarkers combination
Claim 9 requires:
- biomarkers comprise ALT and AST.
Scope implication:
- Tightest variant among the biomarker claims; ALT/AST-only protocols have the highest overlap.
What is the claim “center of gravity”? (Scope Map)
Protected “process steps”
| Claim element |
What triggers/controls it |
What is protected |
| IPF patient population |
Condition must be IPF |
Disease context |
| Trigger |
Grade 2 abnormality in liver function biomarkers after pirfenidone |
Conditional dosing |
| Phase (a) |
Doses < 2400 mg/day for a time period |
Down-titration below full dose |
| Phase (b) |
Doses 2400 mg/day or 2403 mg/day |
Re-escalation to full dose targets |
| Optional discontinuation |
Stop until normal limits, or fixed ~1 week |
Hold/restart variants |
| Biomarkers |
ALT/AST/bilirubin/alk phos; or ALT+AST |
Biomarker-defined safety protocol |
| Monitoring |
Measure biomarkers during step (a) |
Active monitoring while dose reduced |
| Administration format |
Three times daily with food |
Dosing schedule constraint |
Most enforceable “hard numbers”
- 2400 mg/day and 2403 mg/day as the re-escalation endpoint.
- Lower-dose anchors: 1600/1602 mg/day and 800/801 mg/day plus staged and hold variants.
- Time: about one week and/or “until biomarkers are within normal limits.”
How broad is the protection? (Infringement theory vs design-around)
Broadest coverage within the set
- Claim 1 is the broadest because it covers:
- any regimen where (a) is below 2400 mg/day for some time period
- then (b) is 2400 or 2403 mg/day
- provided the patient had grade 2 liver biomarker abnormality after prior pirfenidone
This means the broadest literal infringement case exists when a regimen uses any sub-2400 mg/day downshift before returning to 2400/2403 mg/day, regardless of the exact low-dose anchor.
Narrower coverage in dependent claims
Dependent claims narrow by imposing additional constraints such as:
- exact low-dose amounts (800/801 and 1600/1602),
- explicit interruption patterns (one-week discontinuation),
- specific biomarker sets (ALT/AST/bilirubin/ALP; or ALT+AST),
- monitoring “during step (a),”
- TID administration “with food.”
Potential design-around levers (claim language–driven)
While infringement must be evaluated against full claim construction, the textual boundaries imply the following levers:
- avoid the 2400 mg/day or 2403 mg/day re-escalation targets (if clinically and legally feasible),
- avoid grade 2 as the triggering criterion in the protocol description or operational logic,
- avoid “lower than 2400 mg/day” sequence by using a different decision structure (risk: may still read under claim construction),
- avoid measuring biomarkers during step (a) if aiming to steer clear of Claim 8,
- avoid “selected from the group consisting of” biomarkers if using a different monitoring framework for decisioning (risk: practical regulatory norms for liver safety are likely to overlap with ALT/AST).
Claim construction pressure points
These are the terms likely to control the scope in litigation or prosecution history-based arguments:
- “grade 2 abnormality”
- The claim requires this grade threshold as part of the patient condition after exposure.
- “one or more biomarkers of liver function”
- The biomarker identity matters for Claims 7 and 9.
- “administering… at doses lower than 2400 mg/day for a time period”
- “Lower than” is strict; the low-dose endpoints in dependent claims help interpret boundaries.
- “2400 mg/day or 2403 mg/day”
- These are exact endpoint options; using another full-dose target would not satisfy Claim 1’s (b) element literally.
- “measuring… during step (a)”
- Timing is explicit for Claim 8.
Where does this sit in the broader pirfenidone IPF safety-dosing landscape? (Landscape framing)
Functional placement
The claimed method targets the safety management problem: liver enzyme/bilirubin elevations during pirfenidone therapy in IPF. It is a dose-reduction and re-escalation algorithm keyed to grade 2 liver biomarker abnormalities, with defined low-dose steps and durations.
Landscape implications for R&D and commercialization
For payer, protocol, and labeling-driven practice:
- A method that mirrors the claimed algorithm can face direct method claim exposure when all elements are performed.
- Product and clinical programs that publish or operationalize a grade 2 liver biomarker response protocol using the same dose sequencing and endpoints face higher risk.
Patent landscape: what can be inferred from the claim set alone (and what cannot)
Only the claim text was provided. Without the patent’s full specification, priority data, prosecution history, and citation tree, it is not possible to map:
- claim-to-family priority alignment,
- examiner-cited art,
- family members and jurisdictional forks,
- whether the claims are narrowed by amendments or surrendered subject matter,
- whether this patent is a continuation, reissue, or split from an earlier application.
This section therefore focuses on landscape structure that is directly supported by the claim text: the patent is a method-of-use / method-of-treatment covering a specific dosing algorithm in IPF patients with grade 2 liver biomarker abnormalities.
Landscape “nodes” that typically matter for this patent type
| Node |
What to look for |
Why it matters to this patent |
| Related method patents on liver monitoring |
Other dose-management algorithms tied to ALT/AST/bilirubin/ALP grades |
Overlap risk if algorithms differ in grade threshold or dosing endpoints |
| Pirfenidone dosing regimen patents |
Dosing amounts, titration patterns, restart rules |
Potential overlap if other patents claim alternative recovery sequences |
| Formulation/dosing-frequency patents |
Once- or twice-daily or different with-food constraints |
Claim 6 adds a schedule with food; alternate regimens can avoid that dependent claim |
| Labeling-driven protocols |
Conformity to safety guidance |
Claims may be used to attack implementation of label-equivalent protocols if elements match |
Key Takeaways
- US 7,566,729 protects a liver-biomarker–guided pirfenidone dose reduction and re-escalation method for IPF patients who show grade 2 liver function biomarker abnormalities after pirfenidone.
- Claim 1 is the breadth anchor: step (a) is any pirfenidone dose below 2400 mg/day for a time period, followed by step (b) at 2400 mg/day or 2403 mg/day.
- Dependent claims tighten scope using specific recovery regimens: 1600/1602 (Claim 3), 800/801 then 1600/1602 (Claim 4), and discontinuation for ~1 week then 800/801 then 1600/1602 (Claim 5).
- The patent also constrains implementation details via TID with food (Claim 6), defined biomarker sets (Claims 7 and 9), and measurement during step (a) (Claim 8).
- From an infringement-control perspective, the numerical endpoints (2400 and 2403 mg/day) and grade 2 trigger are the most operationally decisive elements.
FAQs
-
Is the patent about pirfenidone treatment for IPF in general?
No. It is specifically about managing pirfenidone dosing after grade 2 liver biomarker abnormalities by reducing to below 2400 mg/day and then returning to 2400/2403 mg/day.
-
What is the key “re-escalation” dose in Claim 1?
2400 mg/day or 2403 mg/day.
-
Does the patent require a specific low dose in Claim 1?
Claim 1 requires only that step (a) uses doses lower than 2400 mg/day; specific values like 800/801 and 1600/1602 appear in dependent claims.
-
Which liver biomarkers are explicitly covered?
ALT, AST, bilirubin, and alkaline phosphatase (Claim 7). A tighter version is ALT and AST (Claim 9).
-
Does the patent specify timing and administration frequency?
Yes. Dependent Claim 6 specifies three times per day with food. Dependent Claims 3-5 specify about one week durations and stop-and-restart patterns.
References
[1] United States Patent US 7,566,729. (Claims text as provided by user).
